Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

The discussion focuses on how diagnostic information can guide time-sensitive treatment decisions in the emergency room.

Rhea-AI Summary

QuidelOrtho (QDEL) highlighted episode 61 of its Science Bytes podcast on September 24, 2026, focusing on sepsis diagnosis in emergency care.

Hosted by Josh Casey, the episode features medical science liaison Chris Sanchez discussing early testing and the difficulty of distinguishing bacterial from viral infections. It also covers serial procalcitonin testing, which measures a blood marker over time, to help clinicians identify when antibiotics may be stopped or reduced.

Key Figures

Sepsis death or hospice outcome: 1 in 5 adults; 1 in 10 children

Sepsis death or hospice outcome

1 in 5 adults; 1 in 10 children

Among people who contract sepsis

Key Terms

procalcitonin, fluid resuscitation

2 terms

procalcitonin medical

"Serial procalcitonin testing aids clinicians in identifying opportunities"

A peptide produced in the body that becomes elevated in the blood during systemic bacterial infections and sepsis, used clinically as a diagnostic biomarker to help detect and track bacterial inflammation. Think of it like a smoke detector for bacterial infection: its level helps clinicians distinguish bacterial causes from nonbacterial illnesses. Its commercial and regulatory importance stems from use in diagnostic tests, laboratory services, clinical decision algorithms, and related reimbursement and approval pathways.

fluid resuscitation medical

"overuse of fluid resuscitation methods increase mortality rates"

Fluid resuscitation is the medical practice of giving fluids, usually intravenously, to restore a patient’s blood volume and circulation when they are dehydrated, in shock, or losing blood. It matters to investors because it is a core treatment in emergency care, surgery, and critical-care settings that drives demand for IV fluids, infusion devices, monitoring equipment and related drugs; like refilling a car’s fuel tank to get it running again, it restores vital function so other treatments can work.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates.

Hosted by Josh Casey, this episode features QuidelOrtho's Medical Science Liaison Chris Sanchez, MSN, RN, who brings to light diagnostic strategies necessary to support critically ill patients. Chris brings firsthand experience implementing diagnostic strategies as well as caring for critically ill patients.

Key Insights:

• One in five adults and one in ten children who contract sepsis die or go into hospice care
• Delayed diagnosis and overuse of fluid resuscitation methods increase mortality rates
• Inability to distinguish between bacterial and viral infections handicaps clinicians in making the right treatment decisions
• Bacterial infections that go unrecognized may quickly escalate into sepsis
• Swift diagnosis can mitigate these challenges as well as the overuse of antibiotics
• Serial procalcitonin testing aids clinicians in identifying opportunities for antibiotic discontinuation or de-escalation
• Early testing presents opportunities for quick intervention as well as targeted treatment

The conversation illuminates how rapid, actionable diagnostic information can aid emergency medicine physicians in making time-critical decisions in the ER.

Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
media@QuidelOrtho.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/early-intervention-aids-emergency-medicine-teams-in-identifying-and-personalizing-sepsis-treatment-302888208.html

SOURCE QuidelOrtho Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Where can I listen to QuidelOrtho's Science Bytes episode on sepsis?

The episode is available on major streaming platforms and at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.